330 studies found for:    Spasticity
Show Display Options
Download search resultsDownload the search results for:
Spasticity (330 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: Sativex®;   Drug: Placebo
2 Recruiting Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Spasticity in Persons With Spinal Cord Injury
Conditions: Spinal Cord Injury;   Spasticity
Intervention: Device: Duolith® SD 1 "T-Top" (Storz Medical AG, Switzerland)
3 Recruiting Reliability of an Algorithm to Diagnose Spasticity
Condition: Spasticity
Intervention:
4 Completed Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
Conditions: Spasticity;   Cerebral Palsy
Intervention: Drug: baclofen
5 Not yet recruiting Developing and Testing a Comprehensive MS Spasticity Management Program
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Behavioral: Spasticity: Take Control
6 Completed Prevalence of Spasticity in Veterans Living in a Long-term Care Facility
Condition: Spasticity
Intervention:
7 Completed
Has Results
Retrospective Study of Patients With Spasticity in the Spanish Population
Condition: Muscle Spasticity
Intervention: Other: No treatment
8 Completed
Has Results
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: Sativex;   Drug: Placebo
9 Completed
Has Results
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
Conditions: Spinal Cord Injury;   Muscle Spasticity
Interventions: Drug: Fampridine-SR;   Other: Placebo
10 Completed
Has Results
Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
Conditions: Spinal Cord Injury;   Muscle Spasticity
Interventions: Drug: Fampridine-SR;   Drug: Placebo
11 Completed Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Condition: Muscle Spasticity
Intervention: Drug: Tizanidine (sublingual or oral)
12 Unknown  Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
Condition: Muscle Spasticity Due to Multiple Sclerosis
Interventions: Drug: BGG492;   Drug: Placebo
13 Recruiting Early Use of Botulinum Toxin in Spasticity Post Stroke.
Conditions: Stroke;   Muscle Spasticity;   Contracture
Interventions: Drug: onabotulinumtoxinA;   Drug: Placebo
14 Completed
Has Results
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: Sativex®;   Drug: Placebo
15 Withdrawn Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
Condition: Spasticity
Intervention: Device: Prometra Programmable Implantable Pump System
16 Completed Vanderbilt University Spasticity Management Program Evaluation Plan
Condition: Spasticity
Interventions: Drug: Botulinum Toxin Type A;   Drug: Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
17 Suspended Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs
Condition: Muscle Spasticity
Intervention: Other: No Intervention
18 Unknown  A Prospective Study of Spasticity in Individuals With Multiple Sclerosis
Condition: Spasticity
Intervention:
19 Completed Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: arbaclofen;   Drug: baclofen;   Drug: Placebo
20 Recruiting Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Conditions: Cerebral Palsy;   Spasticity
Interventions: Drug: IncobotulinumtoxinA (8 Units per kg body weight);   Drug: IncobotulinumtoxinA (6 Units per kg body weight);   Drug: IncobotulinumtoxinA (2 Units per kg body weight)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years